Literature DB >> 7740752

Neutralizing antibodies against Shiga-like toxins from Escherichia coli in colostra and sera of cattle.

F Pirro1, L H Wieler, K Failing, R Bauerfeind, G Baljer.   

Abstract

Previous or present infection with Shiga-like toxin producing E. coli (SLTEC) was detected by an indirect neutralization assay of antibody titer. Bovine colostra and sera blocked the cytotoxic effects of Shiga-like toxin on Vero cell monolayers. SLT neutralizing antibodies were present in 84.0% (189/225) of the colostrum samples from randomly chosen cows in Bavaria, Germany. While all of the colostra with neutralizing activity reacted with SLT-I, only 14.7% neutralized both SLT-I and -II. Approximately 93.0% (37/40) of sera from heifers had SLT neutralizing activity. To quantify the neutralizing antibodies, colostra were tested in the Vero cell assay for their capability to reduce the 50% cytotoxic dose (CD50) of SLT standards, where the neutralizing units/ml (nu/ml) equal the log10 of CD50 reduction. Almost half of reactive colostra (48.7%) reduced the CD50 of the SLT-I standard by 10(4) to 10(5) (4-5 nu/ml). Higher reactivity (5-7 nu/ml) was found in 46.5% of positive colostra. The remaining colostra samples had over 7 nu/ml. To determine if the colostra were blocking receptors for SLT on Vero cells, cells were preincubated with colostra, and SLT was later added. No neutralizing activity was detected, indicating the reactivity of colostra was directed against SLT. When the colostra were subjected to ammonium sulphate precipitation and DEAE anion exchange chromatography, high levels of neutralizing activity were found in the IgG1 containing fractions. Colostrum fractions were tested for SLT-I binding antibodies in a capture ELISA, based on the binding of SLT-I to the toxin receptor analogue P1-glycoprotein. Only fractions from colostra with over 5 nu/ml were reactive in this assay, indicating the ELISA was less sensitive than the Vero cell assay. The results support the theory that SLTEC exposure of cows in Germany is more widespread than expected from epidemiological studies based on bacterial isolation. This possibly indicates a higher risk of human SLTEC infection via beef and milk products.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7740752     DOI: 10.1016/0378-1135(94)00089-f

Source DB:  PubMed          Journal:  Vet Microbiol        ISSN: 0378-1135            Impact factor:   3.293


  20 in total

1.  Shiga toxin 1 from Escherichia coli blocks activation and proliferation of bovine lymphocyte subpopulations in vitro.

Authors:  C Menge; L H Wieler; T Schlapp; G Baljer
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

2.  Strain-dependent cellular immune responses in cattle following Escherichia coli O157:H7 colonization.

Authors:  Alexander Corbishley; Nur Indah Ahmad; Kirsty Hughes; Michael R Hutchings; Sean P McAteer; Timothy K Connelley; Helen Brown; David L Gally; Tom N McNeilly
Journal:  Infect Immun       Date:  2014-09-29       Impact factor: 3.441

3.  Shiga Toxin-Producing E. coli in Animals: Detection, Characterization, and Virulence Assessment.

Authors:  Stefanie A Barth; Rolf Bauerfeind; Christian Berens; Christian Menge
Journal:  Methods Mol Biol       Date:  2021

4.  A standard immunoglobulin preparation produced from bovine colostra shows antibody reactivity and neutralization activity against Shiga-like toxins and EHEC-hemolysin of Escherichia coli O157:H7.

Authors:  R Lissner; H Schmidit; H Karch
Journal:  Infection       Date:  1996 Sep-Oct       Impact factor: 3.553

5.  Bovine immune response to shiga-toxigenic Escherichia coli O157:H7.

Authors:  Mark A Hoffman; Christian Menge; Thomas A Casey; William Laegreid; Brad T Bosworth; Evelyn A Dean-Nystrom
Journal:  Clin Vaccine Immunol       Date:  2006-10-18

6.  Antiviral activity of shiga toxin 1: suppression of bovine leukemia virus-related spontaneous lymphocyte proliferation.

Authors:  W A Ferens; C J Hovde
Journal:  Infect Immun       Date:  2000-08       Impact factor: 3.441

7.  Neutralizing antibodies to Escherichia coli Vero cytotoxin 1 and antibodies to O157 lipopolysaccharide in healthy farm family members and urban residents.

Authors:  D Reymond; R P Johnson; M A Karmali; M Petric; M Winkler; S Johnson; K Rahn; S Renwick; J Wilson; R C Clarke; J Spika
Journal:  J Clin Microbiol       Date:  1996-09       Impact factor: 5.948

8.  Bovine colostrum contains immunoglobulin G antibodies against intimin, EspA, and EspB and inhibits hemolytic activity mediated by the type three secretion system of attaching and effacing Escherichia coli.

Authors:  Daniel A Vilte; Mariano Larzábal; Angel A Cataldi; Elsa C Mercado
Journal:  Clin Vaccine Immunol       Date:  2008-06-18

9.  Do camels (Camelus dromedarius) play an epidemiological role in the spread of Shiga Toxin producing Escherichia coli (STEC) infection?

Authors:  A El-Sayed; S Ahmed; W Awad
Journal:  Trop Anim Health Prod       Date:  2007-12-19       Impact factor: 1.559

10.  Antiviral activity of shiga toxin requires enzymatic activity and is associated with increased permeability of the target cells.

Authors:  Indira Basu; Witold A Ferens; Diana M Stone; Carolyn J Hovde
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.